Navigation Links
Optimizing cell therapy against tumors is a balancing ACT

Adoptive cell transfer (ACT) therapy is used to treat patients with metastatic solid tumors. ACT involves the removal of some of the patient's cancer cells, and some of their immune T cells. When the cells are mixed together, specific parts of the cancer cells that stimulate the T cells to cause an immune attack can be identified. The T cells get expanded and re-infused into the patient to mount an immunological, anti-cancer response against the tumors. One of the challenges faced is selecting the appropriate T cells with proper antigen specificity.

In a new study appearing in the June 1 print issue of The Journal of Clinical Investigation, Nicholas Restifo and colleagues identified which cells are optimal for treating large, vascularized, established tumors. The authors use a mouse model that mimics the human clinical situation. They find that phenotypic and functional qualities of T cells are associated with the ability of ACT to cause regression of large, established melanomas. Seemingly paradoxical, naïve and early effector T cells are more effective for tumor treatment than more differentiated T cells.

In an accompanying commentary, Daniel Speiser and Pedro Romero write, "optimal therapeutic efficacy may depend on different T cell selection and preparation strategies" and these findings indicate that a pragmatic strategy for ACT is to keep the in vitro T cell expansion phase as short as possible to keep them naïve. These findings are important for development of improved adoptive immunotherapy approaches for treating tumors and established infectious diseases.

TITLE: Acquisition of full effector function in vitro paradoxically impairs the in vivo anti-tumor efficacy of adoptively transferred CD8+ T cells

TITLE: Towards improved immunocompetence of adoptively transferred CD8+ T cells


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2019)... VIEW, Calif. (PRWEB) , ... March 13, 2019 , ... ... up to 45 percent of the world’s population. One billion people ... breathing is interrupted during sleep - more than 80 percent of whom go undiagnosed. ...
(Date:3/9/2019)... ... ... Murrieta Genomics , the genomic sequencing business incubator, is pleased to ... California Riverside’s EPIC SBDC focused on research funding by U.S. Small Business Administration. The ... 2019. The location is the Highlander Union Building, Room 302 South on the University ...
(Date:3/9/2019)... ... March 09, 2019 , ... Hello Bio announces ... exciting compounds for scientists studying GPCR and DREADD signalling. Hello Bio has been ... Institute of Neurological Disorders and Stroke, both institutes of the National Institutes of ...
Breaking Biology News(10 mins):
(Date:3/11/2019)... ... 2019 , ... USDM Life Sciences and Generis have ... in GxP compliance for the life sciences industry. USDM Cloud Assurance delivers ... compliance for Generis’ flagship product, CARA. , Presentation One:, What: ...
(Date:3/5/2019)... ... March 05, 2019 , ... ... engineering firm with regulatory filing authorities, logistics network experts, and experienced integrated staffing ... its participation in the Inc. Verified Profile program, Inc. editors independently reviewed the ...
(Date:2/26/2019)... ... February 26, 2019 , ... ... Co-Founder Dr. Thomas Villani developed the Visikol® tissue clearing technology for improved tissue ... transitioned from a products focused company to primarily a services focused company. ...
(Date:2/19/2019)... ... 19, 2019 , ... VetStem Biopharma has long been a leader ... 2018, VetStem authorized the formation of Personalized Stem Cells, Inc (“PSC”), a human adipose ... and FDA filings to launch into human stem cell clinical therapy. PSC will ...
Breaking Biology Technology: